MBRX News and Press, Moleculin Biotech Inc. From 04/21/21

Shares of Moleculin Biotech Inc. (NASDAQ:MBRX) traded at a new 52-week low today of $3.12. Approximately 7.7 million shares have changed hands today, as compared to an average 30-day volume of 1.8 million shares. Moleculin Biotech Inc. share prices have moved between a 52-week high of $9...

Galectin Therapeutics (GALT) +27% as its belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer.Bit Digital (BTBT) +17%.UTStarcom Holdings (UTSI) +14%.Greenwich LifeSciences (GLSI) +15% after update on GP2 phase III clinical trial sesign.Moleculin Biotech (MBRX)...

The FDA has granted Rare Pediatric Disease Designation ((RPD)) to Moleculin Biotech's (MBRX) p-STAT3 inhibitor, WP1066, for the treatment of ependymoma, a rare type of tumor that can form in the brain or spinal cord.Rare Pediatric Disease status provides for the issuance of a rare pediatric d...

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma PR Newswire HOUSTON , April 14, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stag...

Moleculin Biotech (MBRX) announces the engagement of contract research organization IQVIA Biotech to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.WP1122 is a prodrug of 2-DG, a well-known antimetabolite with the ability to inhibit...

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial PR Newswire HOUSTON , April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portf...

Gainers: Novan (NOVN) +17%, ShockWave Medical (SWAV) +17%, Orphazyme (ORPH) +13%, Moleculin Biotech (MBRX) +14%, Annovis Bio (ANVS) +8%.Losers: Wave Life Sciences (WVE) -30%, Trxade (MEDS) -27%, Universe Pharmaceuticals (UPC)&#x...

VirTra (VTSI) +56% on Q4 results.Color Star Technology Co., Ltd. (CSCW) +56% as company to develop NFT.Performant Financial Corporation (PFMT) +26%.Monopar Therapeutics (MNPR) +18% on preclinical update of its uPA.Moleculin Biotech (MBRX) +18% on FDA's fast track desi...

Moleculin Biotech (MBRX) has climbed ~18.1% in the pre-market after announcing that the FDA has approved its request for Fast Track Designation for its experimental drug, Annamycin for the treatment of soft tissue sarcoma (“STS”) lung metastases.“We now have pot...

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases PR Newswire HOUSTON , March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage phar...